Fried Frank acted as counsel to Evercore as financial advisor to Takeda Pharmaceutical Company in its £46 billion acquisition of Shire Plc. Under the terms of the acquisition, each Shire shareholder will be entitled to receive, for each Shire share, US$30.33 in cash and either 0.839 new Takeda shares or 1.678 Takeda ADSs. The acquisition has been approved by Takeda's and Shire's Board of Directors. The acquisition creates a global, values-based, R&D driven biopharmaceutical leader incorporated and headquartered in Japan, with an attractive geographic footprint. The merger provides the scale to drive future development, strengthens Takeda's presence across two of its three core therapeutic areas, and provides leading positions in rare diseases and plasma-derived therapies.
The Fried Frank team was led by partners Philip Richter and Scott B. Luftglass and associates Roy Tannenbaum and Anne Aufhauser.